Moreover, a meta-analysis of seven randomized trials involving 13,864 women with early-stage HER2-positive breast cancer confirmed that adding trastuzumab to chemotherapy significantly reduces the risk of recurrence and death, with benefits persisting for up to 10 years. This evidence concerns the gene ERBB2 and breast carcinoma.